Alkermes said its "continues to make meaningful progress on the previously announced planned separation of the company’s oncology business." The separation "would allow Alkermes to maintain its focus on researching, developing and commercializing therapies for people living with complex neurological conditions and is expected to accelerate and enhance the profitability of the remaining neuroscience business," the company said in its earnings release. Alkermes continues to expect to complete the separation in the second half of 2023, subject to various customary conditions, including final approval from Alkermes’ board of directors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALKS:
- Alkermes arbitration award better than expected, says Mizuho
- Alkermes price target raised to $31 from $29 at JPMorgan
- Alkermes receives second interim award in Janssen arbitration
- Alkermes submits Form 10 to SEC for planned separation of oncology business
- Alkermes price target raised to $37 from $36 at Mizuho